FDA Declines Rush Request for Alzheimer’s Drug Donanemab
By
Alexandra Marvar
| January 23rd, 2023
The FDA rejected Eli Lilly’s request to expedite the approval process for experimental Alzheimer’s drug donanemab, but the drug’s Phase 3 trial is carrying…